Followers | 63 |
Posts | 24415 |
Boards Moderated | 0 |
Alias Born | 11/23/2016 |
Thursday, April 27, 2017 5:55:34 PM
I do agree that the ALDX choice of 0.1% solution is worrisome, particularly as I have seen no dose response data or explanation of this assumed minimum response dose.
As you said, nor is it clear what ALDX have agreed with the FDA. Is it confirmation of statistical significance against placebo for the 0.5% dose, while simply accepting whatever minimal dose effect we get. Or is there some set expectation from the 0.1% arm.
I don't know, but CEO Brady seems to think it is all Dandy. I guess only time will tell.
Recent ALDX News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:22 PM
- Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 01:02:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 10:07:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 09:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:48 AM
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap • Business Wire • 08/08/2024 11:00:00 AM
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap • Business Wire • 08/07/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/01/2024 09:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:11:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:03:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:40 AM
- Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 11:01:34 AM
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease • Business Wire • 06/13/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Investor Roundtable Q&A • Business Wire • 06/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:09 PM
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease • Business Wire • 05/08/2024 11:00:00 AM
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day • Business Wire • 04/25/2024 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM